FDA Orders New Eye-Risk Warning Labels for Ozempic, Wegovy

The US Food and Drug Administration (FDA) has ordered new warning labels for several widely used weight-loss and diabetes drugs, citing a rare risk of permanent vision loss.

The affected medicines, including Ozempic, Wegovy, and Zepbound, belong to a class of drugs known as GLP-1 receptor agonists, which have surged in popularity in recent years for their effectiveness in weight management.

According to the FDA, a small number of patients taking these drugs have experienced vision problems that did not resolve, prompting regulators to require clearer disclosure of the risk on product labelling.

The agency has not indicated that the overall safety profile of GLP-1 drugs has changed substantially, but it is requiring manufacturers to update prescribing information so that doctors and patients are fully informed before starting treatment.

GLP-1 drugs function by mimicking a natural hormone that regulates appetite and blood glucose, helping users feel full and, in many cases, lose significant weight.

Because of this effectiveness, the drugs have become some of the best-selling pharmaceutical products in the United States, used by millions of people for both weight loss and the management of type 2 diabetes.

The new labelling requirement reflects a broader pattern in which regulators continue to monitor post-market safety data even after a drug has received approval, adjusting guidance as new evidence emerges.

Health authorities have emphasised that the vision-loss risk appears to be rare, and they have not advised patients to stop taking the medications without consulting their doctors.

Pharmaceutical companies producing these drugs are expected to comply with the FDA's labelling order, which will make the rare adverse effect an officially recognised risk associated with the treatment.

The development is likely to renew public discussion about the long-term safety of GLP-1 drugs as their use continues to expand globally.